Amgen names Elliott M. Levy, M.D., Senior Vice President, Global Development
20 August 2014 | By Amgen
Amgen announced that Elliott M. Levy, M.D., has been named senior vice president, Global Development, effective Sept. 8, 2014...
List view / Grid view
News
Novartis provides drug candidate compounds to TB Alliance
20 August 2014 | By Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...
Pfizer announces submission of palbociclib New Drug Application to the FDA
19 August 2014 | By Pfizer
Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for palbociclib...
Novo Nordisk accepts fine for violating disclosure obligation in Denmark
19 August 2014 | By Novo Nordisk
Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by Novo Nordisk on 10 December 2013...
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)
19 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections...
Amgen announces positive top-line results from second Phase 3 study of AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis
19 August 2014 | By Amgen
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, receiving hemodialysis, met its primary and all secondary endpoints...
Initiation of Phase 3 trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) approved in the US for the treatment of multiple sclerosis
18 August 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis...
FDA approves Roche’s Avastin plus chemotherapy for treatment of advanced cervical cancer
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma
15 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival...
Pfizer announces FDA acceptance of and priority review designation for biologics license application for investigational meningococcal B vaccine
15 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086...
Sanofi Pasteur announces publication of positive data for Fluzone® high-dose vaccine in The New England Journal of Medicine
14 August 2014 | By Sanofi
Sanofi Pasteur announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was more efficacious in preventing influenza...
AstraZeneca advances tralokinumab to Phase III in severe asthma
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
Advisory committee on Immunization Practices votes to recommend Pfizer’s Prevnar 13® vaccine in adults aged 65 years and older
14 August 2014 | By Pfizer
Pfizer Inc. announced that the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend Prevnar 13®...
